Abstract
Patients with peripheral artery disease (PAD) requiring surgical lower extremity revascularization (LER) are at heightened risk of adverse limb complications, including acute limb ischemia (ALI). VOYAGER PAD demonstrated that rivaroxaban significantly reduces this risk. Bypass is a major component of surgical LER, and procedural success is dependent on quality and type of conduit. The risk of ALI and efficacy of rivaroxaban for VOYAGER PAD surgical patients receiving vein or prosthetic conduit have not been described.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
